标题:Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 ...
1. Mateos MV, Robak P, Hus M, et al. DREAMM-7 update: Subgroup analyses from a phase 3 trial of belantamab mafodotin + bortezomib and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory ...
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said:“The overall survival results from the DREAMM-7 trial underscore the potential for this Blenrep combination to extend the lives of patients with relapsed/refractory multiple myeloma....
Of note, in the CASTOR trial, median OS with DVd was 49.6 months in patients with a median of 2 prior lines of therapy. We will present the results from the second planned interim analysis of DREAMM-7, with an approximate 3.3 years of follow-up; this will provide further insight on ...
Belantamab mafodotin (belamaf) was the first agent approved that targets BCMA as an antibody-drug conjugate (ADC) but was withdrawn after the confirmatory trial did not demonstrate statistical superiority favoring belamaf.3 However, in the past six Declaration of interests N.S.J. has served ...
Of note, in the CASTOR trial, median OS with DVd was 49.6 months in patients with a median of 2 prior lines of therapy. We will present the results from the second planned interim analysis of DREAMM-7, with an approximate 3.3 years of follow-up; this will provide further insight on ...
DREAMM-11 Part 2 (NCT03828292) was a Phase 1, open-label trial to investigate the tolerability, safety, clinical activity, PK, pharmacodynamics (PD) and immunogenicity of belantamab mafodotin in combination with bortezomib or pomalidomide plus dexamethasone. In Arm A, patients received intravenous...
and who have documented disease progression during or after their most recent therapy. Compared to the patient population studied in the DREAMM-7 trial, patients in DREAMM-8 were more heavily pre-treated in that all had prior exposure to lenalidomide, 75% were refractory to lenalidomide, 25% ...
the only other clinical trial designed to prospectively evaluate an anti-myeloma treatment (combination selinexor plus dexamethasone) in patients refractory to at least one PI, one immunomodulatory agent, and daratumumab (as in DREAMM-2), in which an ORR of 26% was reported7. The STORM study ...
Dream Machines V540TU-14NA26 - Intel Ultra 7-155H, 14" QHD+ 120Hz (2880x1800), Intel Arc Graphics, 1TB M.2 PCIe SSD, 32 GB (2x16 GB DDR5), White Color Illuminated Keyboard, Hi-Def Audio, Ultra Slim Add to cart ASUS ROG Zephyrus G14 Gaming and Entertainment Laptop (AMD Ryze...